Imipenem Mixture w/cilastin is a 1:1 mixture of Imipenem and Cilastin, a combination originally developed by Merck & Co in 1985 (trade name Primaxin).
Imipenem is a broad-spectrum β-lactam antimicrobial, a carbapenem effective against extended spectrum beta-lactamase (ESBL) producing Enterobacteriaceae, a group of pathogenic microbes resistant to many first line beta-lactam antibiotics and certain cephalosporins. Cilastatin is a chemical substance which inhibits dehydropeptidase (DHP1), a human enzyme that degrades Imipenem.
Imipenem Mixture w/cilastin is soluble in aqueous solution.
We also offer:
- Imipenem (I001)
|Mechanism of Action||β-lactams interfere with PBP (penicillin binding protein) activity involved in the final phase of peptidoglycan synthesis. PBP’s are enzymes which catalyze a pentaglycine crosslink between alanine and lysine residues providing additional strength to the cell wall. Without a pentaglycine crosslink, the integrity of the cell wall is severely compromised and ultimately leads to cell lysis and death. Resistance to β-lactams is commonly due to cells containing plasmid encoded β-lactamases. Like many members of the carbapenem subgroup, imipenem is highly resistant to β-lactamase activity.|
|Spectrum||Imipenem is a broad spectrum antibiotic targeting a wide range of aerobic and anaerobic Gram-positive and Gram-negative bacteria.|
|Microbiology Applications||Imipenem is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against gram positive and gram negative microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options for infected patients. Representative MIC values include:
|Plant Biology Applications||Imipenem has been shown to be effective against bacteria from the genus Burkholderia, a well described plant pathogen, and was shown to be effective for sour skin (onions), slippery skin (bulbs), and cavity disease (mushrooms)(Sojanova et al, 2007).|
|Molecular Formula||C12H17N3O4S • H2O ; C16H26N2O5S|
|Assay||Imipenem: ≥ 400µg/mg
Cilastatin: ≥ 400µg/mg
Imipenem/Cilastatin: 0.95 - 1.05: 1
Berg PH, Voit EO and White RL (1996) A pharmacodynamic model for the action of the antibiotic Imipenem on Pseudomonas aeruginosa populations in vitro. Bltn. Mathcal. Biol. 58(5):923-938
Chen P et al (2014) Activity of Imipenem against Klebsiella pneumoniae biofilms in vitro and in vivo. Antimicrob. Agents Chemother. 58(2):1208-1213
Lyon JA (1985) Imipenem/cilastatin: The first carbapenem antibiotic. Drug Intell Clin Pharm. 19(12):895‐899
Pitout JD, Sanders CC, Sanders WE (1997) Antimicrobial resistance with focus on beta-lactam resistance in Gram-negative bacilli. Am J Med 103:51
|MIC||Stenotrophomonas maltophilia (TOT16)| 512 － ?| 659| Stenotrophomonas maltophilia (TOT19)| 256 － ?| 659| Stenotrophomonas maltophilia (TOT43)| 256 － ?| 659| Stenotrophomonas maltophilia (TOT57)| 256 － ?| 659| Stenotrophomonas maltophilia (TOT8)| 512 － ?| 659||